about
Detection of t(4;14)(p16.3;q32) chromosomal translocation in multiple myeloma by reverse transcription-polymerase chain reaction analysis of IGH-MMSET fusion transcriptsABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano LinfomiPrimary plasma cell leukemia 2.0: advances in biology and clinical management.Absolute Monocyte Count and Lymphocyte-Monocyte Ratio Predict Outcome in Nodular Sclerosis Hodgkin Lymphoma: Evaluation Based on Data From 1450 Patients.Inhibiting angiogenesis and tumorigenesis by a synthetic molecule that blocks binding of both VEGF and PDGF to their receptors.Validation of the international prognostic index in working formulation group A low-grade non-Hodgkin's lymphoma: retrospective analysis of 137 patients from the Gruppo Italiano per lo Studio dei Linfomi registry.A variant of ProMACE-CytaBOM chemotherapy for non-Hodgkin's lymphoma with threefold higher drug dose size but identical cumulative dose intensity. A pilot study of the Italian lymphoma study group (GISL).Clinical activity and safety of combination immunotherapy with IFN-alpha 2a and Rituximab in patients with relapsed low grade non-Hodgkin's lymphoma.Prospective study of indolent non-follicular non-Hodgkin's lymphoma: validation of Gruppo Italiano per lo studio dei linfomi (GISL) prognostic criteria for watch and wait policy.Phase II fludarabine and cyclophosphamide for the treatment of indolent B cell non-follicular lymphomas: final results of the LL02 trial of the Gruppo Italiano per lo Studio dei Linfomi (GISL).Immune thrombocytopenia in patients with chronic lymphocytic leukemia is associated with stereotyped B-cell receptors.Bendamustine salvage therapy for T cell neoplasms.A phase II study of bendamustine in combination with rituximab as initial treatment for patients with indolent non-follicular non-Hodgkin lymphoma.A Multicenter Phase II Study of Twice-Weekly Bortezomib plus Rituximab in Patients with Relapsed Follicular Lymphoma: Long-Term Follow-Up.Monocyte count at diagnosis is a prognostic parameter in diffuse large B-cell lymphoma: results from a large multicenter study involving 1191 patients in the pre- and post-rituximab eraChromosome 1 abnormalities in elderly patients with newly diagnosed multiple myeloma treated with novel therapiesNongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue.Long-Term Results of the HD2000 Trial Comparing ABVD Versus BEACOPP Versus COPP-EBV-CAD in Untreated Patients With Advanced Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi.Proposal and validation of prognostic scoring systems for IgG and IgA monoclonal gammopathies of undetermined significance.DNA methylation profiling identifies two splenic marginal zone lymphoma subgroups with different clinical and genetic features.Analysis of alterations of oncogenes and tumor suppressor genes in chronic lymphocytic leukemia.BCL-6 mutations in normal germinal center B cells: evidence of somatic hypermutation acting outside Ig loci.Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells.A compendium of DIS3 mutations and associated transcriptional signatures in plasma cell dyscrasias.Molecular spectrum of BRAF, NRAS and KRAS gene mutations in plasma cell dyscrasias: implication for MEK-ERK pathway activation.Bisphosphonate-associated osteonecrosis of the jaw: a review of 35 cases and an evaluation of its frequency in multiple myeloma patients.Outcome prediction of diffuse large B-cell lymphomas associated with hepatitis C virus infection: a study on behalf of the Fondazione Italiana LinfomiPrimary plasma cell leukemia in the era of new drugs: has something changed?Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation guidelines for the management of indolent, nonfollicular B-cell lymphoma (marginal zone, lymphoplasmacytic, and small lymphoAntiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi.Molecular events underlying interleukin-6 independence in a subclone of the CMA-03 multiple myeloma cell line.Neutrophil-lymphocyte ratio at diagnosis is an independent prognostic factor in patients with nodular sclerosis Hodgkin lymphoma: results of a large multicenter study involving 990 patients.Biological characterization of refractory anemia with excess of blasts.Radiation therapy improves treatment outcome in patients with diffuse large B-cell lymphoma.CD26 expression in mature B-cell neoplasia: its possible role as a new prognostic marker in B-CLL.Molecular spectrum of TP53 mutations in plasma cell dyscrasias by next generation sequencing: an Italian cohort study and overview of the literature.Prognostic relevance of serum beta2 microglobulin in patients with follicular lymphoma treated with anthracycline-containing regimens. A GISL study.The prevalence and clinical implications of c-kit expression in plasma cell myeloma.Genomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma.Prognosis of follicular lymphoma: a predictive model based on a retrospective analysis of 987 cases. Intergruppo Italiano Linfomi.
P50
Q28143830-CD394B36-E3CF-43C1-979C-4604CCF58E26Q28273184-92EE5179-ACDD-447F-9BF3-B40EB2347D4CQ30243927-2F6E3E00-D811-4768-AC62-A57BF03FDDE4Q30966717-03454B92-7BE6-4523-BC1B-9F8A28843D5EQ33215197-16B45BB0-2155-40B6-ACC6-3BB9E6BF2C18Q33331546-E863220F-E7ED-46AD-9F52-AB4BDFA12ADBQ33331694-2954D6AE-D842-4E63-891C-009703E7724CQ33338804-A7005600-232D-4F49-AB5A-EA55DAF05BACQ33345685-B9840208-4C88-4DCE-AAAA-242E09F1717FQ33391919-438D66FC-09D1-4768-BF9F-6B3826CC5516Q33399624-6B2803A8-6D60-4547-B395-B090B75D407FQ33407099-A0358071-D17C-443A-A4F8-EE2178A6E61FQ33425935-4A42D341-E91B-46AF-821A-88BEB72FE615Q33436585-90DD2C72-77B8-4B69-968E-0EF32ED14994Q33558130-5A04B3CA-9862-4DEB-81F8-1660B09E8770Q34272540-C074B185-3FCD-4FD8-8B03-2D5E7B057B18Q34529373-50E2CE28-6149-49EF-864B-69AD8A2081C3Q34675007-3985C308-AA19-4231-9652-0D642C6A7200Q34985781-0E1DABD9-7349-4DE5-9980-E97A94339E71Q35561291-01F5B41D-A667-4307-862B-38BE0211E113Q35834161-893C1980-3953-4761-9B26-6C115BE634CFQ36322298-134807B7-D38A-4751-AAB3-173A37839701Q36369648-05F752E3-C8DA-489E-9FC4-2AED5C194D47Q36413387-D3B6A228-7058-4810-9810-7A5BACF2DD44Q36414422-3E9C9359-5C06-462A-A617-5B94FB9E1753Q36746430-F18DAA95-CB74-43B3-9856-FA6D2E56E5C3Q37618904-475D0063-1CC7-47CB-BADD-0A7B450F9270Q37896333-18F6AD46-9DCB-4DDA-BF4B-B87540C010D5Q38238460-E1F84057-9AC2-4A25-B7F3-EAFEE250AB97Q38878814-AEA1B22E-E911-493A-B361-3074D21D58CBQ39044553-D18D814C-1C13-4C44-BC7E-5D17E2E7CF05Q39239606-ED4D82AB-B090-4DD1-822C-DB1B914E3FA8Q39601730-1712866D-15ED-457D-8979-9CCF947433B7Q39740601-2B45AE49-B44A-4DFE-A73D-B3A60D7A1C27Q39999150-C145FDD5-6135-488D-BB07-B0B7EDC1071DQ40002181-8F3B029C-AD71-4297-B1F6-25A6F763A0F2Q40152757-0B51E770-2E56-4A20-9563-D971B8A8599AQ40290435-25401ECF-34F5-45B6-9F77-5F3E8DA14E1FQ40330626-7DAA1E9F-F23D-4C05-97A5-383FA02BF930Q40627031-C4120C46-9BC0-414E-BB89-AC6586FE7D66
P50
description
hulumtues
@sq
researcher
@en
հետազոտող
@hy
name
Luca Baldini
@ast
Luca Baldini
@en
Luca Baldini
@es
Luca Baldini
@nl
Luca Baldini
@sl
type
label
Luca Baldini
@ast
Luca Baldini
@en
Luca Baldini
@es
Luca Baldini
@nl
Luca Baldini
@sl
prefLabel
Luca Baldini
@ast
Luca Baldini
@en
Luca Baldini
@es
Luca Baldini
@nl
Luca Baldini
@sl
P106
P1153
7006263525
P21
P31
P496
0000-0003-2964-9981